Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) FCF Margin (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of FCF Margin data on record, last reported at 1015.83% in Q4 2025.

  • For Q4 2025, FCF Margin fell 91879.0% year-over-year to 1015.83%; the TTM value through Dec 2025 reached 603.42%, down 49555.0%, while the annual FY2025 figure was 603.42%, 49554.0% down from the prior year.
  • FCF Margin reached 1015.83% in Q4 2025 per ACRS's latest filing, down from 332.07% in the prior quarter.
  • Across five years, FCF Margin topped out at 506.21% in Q3 2024 and bottomed at 1454.44% in Q1 2022.
  • Average FCF Margin over 5 years is 619.67%, with a median of 656.34% recorded in 2021.
  • Peak YoY movement for FCF Margin: skyrocketed 89950bps in 2022, then tumbled -91879bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 1139.91% in 2021, then soared by 79bps to 240.41% in 2022, then skyrocketed by 83bps to 40.99% in 2023, then tumbled by -137bps to 97.04% in 2024, then tumbled by -947bps to 1015.83% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 1015.83% in Q4 2025, 332.07% in Q3 2025, and 563.53% in Q2 2025.